DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. boosted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 555.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,044 shares of the medical device company’s stock after purchasing an additional 30,541 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in DexCom were worth $4,473,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Valley National Advisers Inc. raised its position in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. raised its holdings in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares in the last quarter. Washington Trust Advisors Inc. boosted its stake in DexCom by 120.6% during the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 193 shares during the last quarter. NBC Securities Inc. bought a new position in DexCom during the 3rd quarter valued at $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in DexCom during the 3rd quarter worth $48,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other DexCom news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the completion of the transaction, the chief financial officer now directly owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders sold 190,004 shares of company stock worth $25,610,270 in the last quarter. 0.41% of the stock is owned by corporate insiders.

DexCom Stock Up 1.4 %

Shares of NASDAQ:DXCM traded up $1.72 on Friday, reaching $128.37. The company had a trading volume of 1,778,982 shares, compared to its average volume of 2,993,904. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The stock has a market capitalization of $51.05 billion, a P/E ratio of 82.82, a P/E/G ratio of 2.16 and a beta of 1.23. The stock has a 50-day moving average price of $132.11 and a 200 day moving average price of $119.96. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. On average, equities analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DXCM. Royal Bank of Canada started coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price for the company. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday. Canaccord Genuity Group increased their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Raymond James lifted their price target on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Finally, Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $141.67.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.